Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06140836
Title	A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	lung non-small cell carcinoma
Therapies	Repotrectinib Crizotinib
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| AUT \| ARG